If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    A new 70 µl dose is available for the SP270+ pump!

    Quick Contact
    A new 70 µl dose is available for the SP270+ pump!

    The optimized SP270+ pump is the result of continuous improvements to the SP270 pump platform. Along with these improvements and its Drug Master File, it has been qualified to comply with FDA and EMA requirements.

    The SP270+ 70µl dose is ideal for delivering liquid solutions and suspensions for nasal and auricular treatments.

    Available in crimp-on, snap-on and screw-on fitments, SP270+ D70µl is the new reference for consistency and reliability.

    Features and benefits:

    • Good priming and dose consistency through life
    • DMF available
    • Broad range of actuators, suitable for nasal, buccal and auricular applications

    See also

    Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

    The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

    e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

    On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

    Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

    Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

    • Marine Silarbi
    • Product Info
    • English
    • Created 17 Aug 2016
    • Modified 23 Aug 2016
    • Hits 1632
    Roberts Metal Packaging
    SR Packaging
    MRP Solutions